STOCKHOLM – March 16, 2017 – ContextVision, a leading provider of medical imaging software specializing in image analysis and artificial intelligence, received a patent approval on a new skeletal visualization technology for 3D ultrasound.
The technology is based on a visualization software and improves the potential for early discovery of skeletal irregularities in unborn babies.
SkeletalView, the newest unique product feature, integrates into ContextVision’s groundbreaking 3D rendering product, REALiCE®, which is commercially available. SkeletalView enables clinicians to obtain a more accurate view of the fetal skeleton during pregnancy. This feature helps the clinicians examine the fetus for spontaneous fractures and skeletal malformations. It also facilitates the measurement of bone structures.
“Our visualization product, REALiCE, has received significant industry attention since its launch. SkeletalView adds further diagnostic value, and we expect that the product will be even more attractive to manufacturers of medical imaging equipment going forward,” said ContextVision’s Vice President, Fredrik Palm.
ContextVision is a medical technology company specializing in image analysis and artificial intelligence. Its cutting-edge technology helps doctors accurately interpret medical images, a crucial foundation for better diagnosis and treatment. As an industry pioneer for more than 30 years, ContextVision is taking a leading position within deep learning, the latest artificial intelligence technology. ContextVision is currently investing significantly in the field to expand its product portfolio. The present product portfolio includes state-of-the-art image enhancement software for 2D/3D/4D ultrasound, MRI, X-ray and mammography which is used by leading equipment manufacturers worldwide. ContextVision is based in Sweden and listed on the Oslo Stock Exchange under the ticker COV.